Please wait a minute...
文章检索
预防医学  2019, Vol. 31 Issue (10): 1007-1011,1016    DOI: 10.19485/j.cnki.issn2096-5087.2019.10.008
  论著 本期目录 | 过刊浏览 | 高级检索 |
低剂量激素补充治疗对年轻宫颈鳞癌患者绝经相关症状的干预效果评价
吴婉莉1, 李春明2, 应倩3, 马麟娟2, 周坚红2, 于爱军1
1.浙江省肿瘤医院妇科,浙江 杭州 310022;
2.浙江大学医学院附属妇产科医院妇科;
3.肿瘤学杂志社
Effect evaluation of the low-dose hormone replacement therapy on menopausal-related symptoms of young patients with cervical squamous cell carcinoma
WU Wan-li*, LI Chun-ming, YING Qian, MA Lin-juan, ZHOU Jian-hong, YU Ai-jun
Department of Gynecology,Zhejiang Cancer Hospital,Hangzhou,Zhejiang 310022,China
全文: PDF(681 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 评价低剂量激素补充治疗(HRT)对年轻宫颈鳞癌患者绝经相关症状的干预效果。方法 选取2016年3月—2018年9月在浙江省肿瘤医院和浙江大学医学院附属妇产科医院确诊为医源性绝经,年龄<45岁的Ⅰ、Ⅱ期宫颈鳞癌患者80例,随机纳入低剂量治疗组(戊酸雌二醇1 mg/d或替勃龙1.25 mg/d)40例,标准剂量治疗组(戊酸雌二醇1 mg/d +替勃龙1.25 mg/d)20例,空白对照组(未行HRT)20例,比较3组患者干预前和干预后1、3、6个月的雌二醇(E2)、促卵泡生成激素(FSH)水平、绝经相关症状(改良Kupperman量表评分)和不良反应发生率。结果 3组患者E2、FSH和改良Kupperman评分差异均有统计学意义(P<0.05);随治疗干预时间增加,低剂量治疗组和标准剂量治疗组的E2水平均先上升后下降,FSH水平和改良Kupperman评分均下降(P<0.05);与空白对照组相比,标准剂量治疗组E2、FSH和改良Kupperman评分变化幅度均更明显,低剂量治疗组E2、FSH水平变化幅度均小于标准剂量治疗组(P<0.05),而改良Kupperman评分下降幅度与标准剂量治疗组接近。低剂量治疗组的不良反应发生率为2.50%,低于标准剂量治疗组的20.00%(P<0.05)。结论 对于年轻宫颈鳞癌患者,低剂量较标准剂量HRT对E2、FSH水平的影响要小,但对绝经相关症状的治疗效果接近。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
吴婉莉
李春明
应倩
马麟娟
周坚红
于爱军
关键词 激素补充治疗宫颈鳞癌绝经干预效果低剂量    
AbstractObjective To evaluate the effect of low-dose hormone replacement therapy(HRT)on menopausal-related symptoms in young patients with cervical squamous cell carcinoma. Methods From March 2016 to September 2018,eighty patients aged 45 years below with cervical squamous cell carcinoma of stage Ⅰ-Ⅱ and iatrogenic menopause were recruited,who were diagnosed at Zhejiang Cancer Hospital and Women's Hospital Affiliated to Medical College of Zhejiang University. Fourty of them performed low dose HRT(1 mg estradiol valerate a day or 1.25 mg tibolone a day),twenty performed standard dose HRT(1 mg estradiol valerate and 1.25 mg tibolone a day),another twenty do not perform HRT as a control group. The levels of follicle stimulating hormone(FSH),estradiol(E2),menopausal symptoms(the improved Kupperman score)and incidence of side effects were assessed before and 1,3,6 months after the intervention. Results There were significant differences in E2 levels,FSH levels and improved Kupperman scores among the low dose group,the standard dose group and the control group(all P<0.05). With the extension of intervention time,E2 levels in the low dose group and the standard dose group increased first and then decreased,FSH levels and improved Kupperman scores decreased(all P<0.05). Compared with the control group,E2 levels,FSH levels and improved Kupperman scores in the standard dose group changed more significantly(all P<0.05). E2 and FSH levels in the low dose group changed less than that in the standard dose group(all P<0.05),while improved Kupperman scores was close to that in the standard dose group. The incidence rate of side effects in the low dose group was 2.50%,which was lower than 20.00% in the standard dose group(P<0.05). Conclusion For young patients with cervical squamous cell carcinoma,using low dose HRT may less affects E2 and FSH levels than using the standard dose,but could achieve similar effects in treatment of menopausal-related symptoms.
Key wordsHormone replacement therapy    Cervical squamous cell carcinoma    Menopause    Intervention effect    Low dose
收稿日期: 2019-04-16      修回日期: 2019-07-28     
中图分类号:  R271.11+6  
通信作者: 于爱军,E-mail:yaj1993@126.com   
作者简介: 吴婉莉,硕士,副主任医师,主要从事妇科肿瘤激素补充治疗等研究工作
引用本文:   
吴婉莉, 李春明, 应倩, 马麟娟, 周坚红, 于爱军. 低剂量激素补充治疗对年轻宫颈鳞癌患者绝经相关症状的干预效果评价[J]. 预防医学, 2019, 31(10): 1007-1011,1016.
WU Wan-li, LI Chun-ming, YING Qian, MA Lin-juan, ZHOU Jian-hong, YU Ai-jun. Effect evaluation of the low-dose hormone replacement therapy on menopausal-related symptoms of young patients with cervical squamous cell carcinoma. Preventive Medicine, 2019, 31(10): 1007-1011,1016.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2019.10.008      或      http://www.zjyfyxzz.com/CN/Y2019/V31/I10/1007
[1] RASOO L N,ROSE P G.Fertility-perserving surgical procedures for patients with gynecologic maligancies[J]. Clin Obset Gynecol,2010,53(4):804-814.
[2] LACEY JV J R,BRINTON L A,BARNES W A,et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix[J]. Gynecol Oncol,2000, 77(1):149-154.
[3] PLOCH E.Hormonal replacement therapy in patients after cervical cancer treatment[J]. Gynecol Oncol,1987,26(2):169-177.
[4] YUK J S,LEE J H,JEON J D,et al.Menopause and blood mercury levels:the Korea national health and nutrition examination survey(KNHANES) 2008-2011[J]. Biol Trace Elem Res, 2014, 162(1-3):1-7.
[5] 李琳,吴洁,蒋小青,等. 江苏省妇女绝经相关因素的流行病学调查[J]. 中华妇产科杂志,2013,48(10):728-733.
[6] 王莉,王雅楠. 围绝经期和绝经后期妇女的生存质量及其与 Kupperman评分的相关性[J]. 中国老年学杂志,2011,31(8):2941-2943.
[7] 胡颖敏,蓝坚华,王佩英,等. 女性围绝经综合征危险因素分析[J]. 预防医学,2017,29(10):1051-1053.
[8] WALLACE W H,THOMSON A B,KELSEY T W.The radiosensitivity of the human oocyte[J]. Hum Reprod,2003 ,18:117-121.
[9] MOSS E L,TANEJA S,MUNIR F,et al.Iatrogenic Menopause after treatment for cervical cancer[J]. Clinical Oncology,2016,(28):766-775.
[10] IBEANU O,MODESITT S C,DUCIE J,et al.Hormone replacement therapy in gynecologic cancer survivors:why not?[J]. Gynecol Oncol,2011,122:447-454.
[11] GORDON J L,GIRDLER S S.Hormone replacement therapy in the treatment of perimenopausal depression[J]. Curr Psychiatry Rep,2014,16(12):517.
[12] 丁月华,金敏娟,王军. 围绝经期女性骨质疏松症激素替代治疗效果观察[J]. 预防医学,2018,30(5):533-535.
[13] 中华医学会妇产科学分会绝经学组. 绝经期管理与激素补充治疗临床应用指南(2012版)[J]. 中华妇产科杂志,2013,48(10):795-799.
[14] EBINA Y,MIKAMI M,NAGASE S,et al.Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer[J]. Int J Clin Oncol,2019,24(1):1-19.
[15] UTIAN W H,ARCHER D F,BACHMANN G A,et al.Estrogen and progestogen use in postmenopausal women:July 2008 position statement of The North American Menopausal Society[J].Menopause,2008,15(4):584-602.
[16] DE VILLIERS T J,HALL J E,PINKERTON J V,et al. Revised global consensus statement on menopausal hormone therapy[J].Climacteric,2016,19:313-315.
[17] 左宏玲,邓燕,王艳芳,等. 低剂量与标准剂量结合雌激素联合不同孕激素应用对围绝经期综合征患者骨密度的影响[J]. 中华妇产科杂志,2018 ,53(4):243-247.
[18] FILES J A,MILLER V M,CHA S S,et al.Effects of different hormone therapies on breast pain in recently postmenopausal women:findings from the Mayo Clinic KEEPS breast pain ancillary study[J]. Womens Health(Larchmt),2014,23(10):801-805.
[19] SCHIERBECK L.Primary prevention of cardiovascular disease with hormone replacement therapy[J]. Climacteric,2015,18(4):492-497.
[20] 纪红. 围绝经期综合征患者更年期症状评分及其影响因素[J]. 中华老年学杂志,2013,33(1):159-160.
[21] 李芸,宋阳,曲凡,等. 低剂量激素补充治疗对绝经后妇女生活质量的影响[J]. 中国医药导报,2015,12(8):70-73.
[22] 丁红岩,徐洪阁,高金瑜,等. 激素替代治疗对宫颈鳞状细胞癌患者术后性激素及肿瘤标志物的影响[J]. 海南医学院学报,2016,22(23):2858-2861.
[1] 孙楷城, 陈劲华, 朱志宏, 黄葵青, 傅爽. 义乌市小学生营养综合干预效果评价[J]. 预防医学, 2022, 34(9): 964-967.
[2] 高玉婕, 陈晓云, 沙艳梅, 王晓芬, 韩光翡, 黎伟娟, 杨蕾, 闻海梅, 胡学琴. 大理白族自治州女性绝经后骨质疏松的影响因素分析[J]. 预防医学, 2022, 34(4): 419-423,428.
[3] 夏青, 戈凌霞, 卢亚运, 钱燕君, 汤雪峰, 刘琴. 绝经早期女性代谢肥胖与颈动脉斑块的关联研究[J]. 预防医学, 2021, 33(10): 1077-1080.
[4] 弥娟妮, 王丽萍, 朱晔, 何艳. 绝经后骨质疏松性再骨折医患联合延续性健康教育效果评价[J]. 预防医学, 2019, 31(9): 963-966.
[5] 朱晓飞, 浦阳, 邱晓玲, 张晓龙. 高职院校学生健康素养微信公众平台干预效果评价[J]. 预防医学, 2019, 31(9): 967-969.
[6] 马林, 黄坚, 陈临节, 楼向明, 周健, 夏建余, 陆晨蕾, 吴红艳, 张治芬. 激素治疗干预对围绝经期女性乳腺病变的影响[J]. 预防医学, 2019, 31(9): 882-885.
[7] 马麟娟,朱帅,许正芬,黄艺舟,傅东霞,徐文娴,周坚红. 围绝经期综合征患者绝经相关症状与激素治疗认知调查[J]. 预防医学, 2019, 31(11): 1172-1175.
[8] 丁月华, 金敏娟, 王军. 围绝经期女性骨质疏松症激素替代治疗效果观察[J]. 预防医学, 2018, 30(5): 533-535.
[9] 汪钱华,冯君,顾燕萍,蒋云珠,王君,朱燕. 民营托幼机构新入园儿童饮食行为干预效果评价[J]. 预防医学, 2018, 30(4): 348-351.
[10] 许海波, 马一鸣, 方志祥. 绝经后骨质疏松患者发生骨折的相关因素分析[J]. 预防医学, 2017, 29(9): 944-945,949.
[11] 李卫珍, 王永英, 李跃红, 祝勤奋, 张建英, 沈玲敏. 海盐县女性围绝经期症状及相关知识调查[J]. 预防医学, 2017, 29(9): 946-949.
[12] 胡争光, 钟羽西, 刘嘉, 张蓉, 孙璟, 王晓洁, 赵德强. 女性围绝经期知识知晓率及需求调查[J]. 预防医学, 2017, 29(9): 950-951,954.
[13] 胡颖敏, 蓝坚华, 王佩英, 汤丽芬, 吴丽东. 女性围绝经期综合征危险因素分析[J]. 预防医学, 2017, 29(10): 1051-1053,1057.
[14] 董艳,柏平华,杨欢敏,顾建萍,倪美良,陈青. 2型糖尿病牙周炎患者健康教育效果评价[J]. 预防医学, 2016, 28(7): 741-743.
[15] 李红儿,童玮如,陆玉莲,沈晓红,徐畅. 宫颈上皮内瘤变Ⅱ级的危险因素及干预效果分析[J]. 预防医学, 2016, 28(6): 634-637.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed